Physician profile
Ratnamani Lingamallu
NPI 1629062393
$4,314.99
in general payments reported to CMS, 2019-2025
22 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $952 · 2021: $1,351 · 2022: $661 · 2023: $361 · 2024: $185 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.06 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,742.44 | 2019-2022 | |
| Optinose US, INC. | $536.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $309.00 | 2019-2025 | Nucala |
| Genzyme Corporation | $210.97 | 2019-2025 | |
| Csl Behring | $191.33 | 2022-2025 | Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $184.75 | 2019-2023 | Fasenra |
| Pharming Healthcare, INC. | $168.89 | 2021-2025 | Ruconest |
| Kaleo, INC. | $163.28 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $156.71 | 2022-2024 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $155.12 | 2020-2023 | Dupixent |
| Ionis Pharmaceuticals, INC. | $136.22 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $72.81 | 2021-2022 | |
| Amgen INC. | $49.03 | 2025 | Tezspire |
| Integra Lifesciences Corporation | $46.58 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Boston Scientific Corporation | $44.60 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $41.33 | 2022-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $25.99 | 2025 | Neffy |
| Aerin Medical INC. | $18.72 | 2025 | |
| Smith+Nephew, INC. | $18.68 | 2025 | Tula |
| Merck Sharp & Dohme LLC | $18.40 | 2023 | |
| Hikma Pharmaceuticals USA | $14.25 | 2022 | |
| Ambu INC. | $9.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratnamani Lingamallu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.